| アブストラクト | OBJECTIVE: Giant cell arteritis (GCA) is an inflammatory disorder of blood vessels that preferentially affects large- and medium-sized arteries. High-dose oral corticosteroids (CS) are the mainstay of GCA therapy. Using data from the UK Clinical Practice Research Datalink, we quantified and compared the incidence of selected potentially CS-associated adverse outcomes in patients with and without GCA. METHODS: We conducted a retrospective follow-up study of GCA and non-GCA patients to examine the incidence of adverse outcomes attributable to CS use. Eligibility criteria for the GCA group included a first-time diagnosis of GCA at age 50 years or older with receipt of >/=1 prescription(s) for prednisolone. GCA patients were matched to a GCA-free comparison group of equal size on age, sex, general practice, and calendar time. We estimated incidence rates and incidence rate ratios (IRRs) for diabetes, osteoporosis, glaucoma, fractures, serious infection requiring hospitalization, and death for GCA and non-GCA patients and compared all-cause hospitalizations between the two groups. RESULTS: The cohort consisted of 5011 GCA and 5011 matched non-GCA patients. Approximately 74% were women, and mean age at GCA diagnosis was 72.9 years. The IR for all outcomes was greater in the GCA group than the non-GCA group. IRRs [95% confidence intervals (CIs)] were as follows: diabetes 1.4 (1.2-1.7), osteoporosis 2.4 (2.1-2.8), fractures 1.4 (1.2-1.6), glaucoma 2.0 (1.6-2.5), serious infection requiring hospitalization 1.5 (1.3-1.7), and death 1.2 (1.0-1.3). CONCLUSION: Compared with age- and sex-matched non-GCA patients, patients with GCA were at increased risk for diabetes, osteoporosis, fracture, and glaucoma and at a marginally increased risk for death. |
|---|
| ジャーナル名 | Seminars in arthritis and rheumatism |
|---|
| 投稿日 | 2016/11/15 |
|---|
| 投稿者 | Wilson, Jessica C; Sarsour, Khaled; Collinson, Neil; Tuckwell, Katie; Musselman, David; Klearman, Micki; Napalkov, Pavel; Jick, Susan S; Stone, John H; Meier, Christoph R |
|---|
| 組織名 | Basel Pharmacoepidemiology Unit, University of Basel, Basel, Switzerland.;Genentech, South San Francisco, CA, USA.;Roche Products Ltd., Welwyn Garden City, UK.;Boston Collaborative Drug Surveillance Program, Boston University School of;Public Health, Lexington, MA, USA.;Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston,;MA, USA.;Basel Pharmacoepidemiology Unit, University of Basel, Basel, Switzerland; Boston;Collaborative Drug Surveillance Program, Boston University School of Public;Health, Lexington, MA, USA; Hospital Pharmacy, University Hospital Basel, Basel,;Switzerland. Electronic address: christoph.meier@usb.ch. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/27839741/ |
|---|
